Gorbunova, Vera
Beck, J. Thaddeus
Hofheinz, Ralf-Dieter
Garcia-Alfonso, Pilar
Nechaeva, Marina
Cubillo Gracian, Antonio
Mangel, Laszlo
Elez Fernandez, Elena
Deming, Dustin A.
Ramanathan, Ramesh K.
Torres, Alison H.
Sullivan, Danielle
Luo, Yan
Berlin, Jordan D.
Article History
Received: 17 May 2018
Revised: 13 September 2018
Accepted: 31 October 2018
First Online: 11 December 2018
Change Date: 26 July 2019
Change Type: Correction
Change Details: The original version of this article contained an error in Figure 1a. The number of patients at risk listed in the Veliparib arm of Figure 1a should have read “65” instead of “35”.An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing interests
: V.G.: consulting/advisory role for Eisai, Pfizer; Speakers’ Bureau for Eisai, Pfizer, Ipsen, Novartis, Eli Lilly. R.K.R.: research support from AbbVie. J.D.B.: Research funding from AbbVie; advisory board for AbbVie. A.T., D.S. and Y.L.: AbbVie employee and owns stock. The remaining authors declare no competing interests.
: This clinical study was conducted in accordance with the protocol, International Conference on Harmonisation Good Clinical Practice guidelines, applicable regulations and guidelines governing clinical study conduct and the ethical principles that have their origin in the Declaration of Helsinki. The study protocol was independently approved by the ethics committees of each participating centre. All patients provided written informed consent before participation in the trial.